Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

Lung cancers with oncogenic mutations in the epidermal growth factor receptor (EGFR) invariably acquire resistance to tyrosine kinase inhibitor (TKI) treatment. Vulnerabilities of EGFR TKI-resistant cancer cells that could be therapeutically exploited are incompletely understood. Here, we describe a...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcar, Lynnette, Bardhan, Kankana, Gheorghiu, Liliana, Dinkelborg, Patrick, Pfäffle, Heike, Liu, Qi, Wang, Meng, Piotrowska, Zofia, Sequist, Lecia V., Borgmann, Kerstin, Settleman, Jeffrey E., Engelman, Jeffrey A., Hata, Aaron N., Willers, Henning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624074/
https://www.ncbi.nlm.nih.gov/pubmed/31216465
http://dx.doi.org/10.1016/j.celrep.2019.05.058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624074/
https://www.ncbi.nlm.nih.gov/pubmed/31216465
http://dx.doi.org/10.1016/j.celrep.2019.05.058

Ejemplares similares